Get the latest news, insights, and market updates on PHR (Phreesia, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Klaviyo, Wingstop among Stephens Best Ideas for 2026
Stephens analysts named their 2026 Best Ideas, with each of the firm’s 23 industry teams identifying one stock they expect to outpace the performance of their industry, the Russell 2000 and the markets in general. The list includes NBT Bancorp (NBTB), Glaukos (GKOS), Bio-Techne (TECH), Phreesia (PHR), QXO (QXO), First Bancorp (FBNC), Klaviyo (KVYO), Upbound Group (UPBD), BrightSpring Health (BTSG), Signet Jewelers (SIG), Exelixis (EXEL), Fifth Third (FITB), Digi International (DGII), FIS (FIS), Jan 3, 2026 - $PHR
Exploring US High Growth Tech Stocks for Potential Expansion
As the U.S. stock market reaches new highs with the S&P 500 closing at a record level and tech stocks leading recent gains, investors are closely watching high-growth sectors for potential opportunities. In this environment, identifying strong tech stocks involves considering their capacity for innovation and resilience amid evolving economic conditions. Dec 24, 2025 - $PHR
Phreesia Stock Has Been Crushed. We’re Standing By Our Pick.
Better than expected third quarter earnings on Dec. 8 did nothing to help as the stock plunged 23% on the day. Let’s unwrap why Phreesia is still a buy for 2026. Phreesia’s platform helps its healthcare clients modernize their patient facing processes and back end workflows. Dec 23, 2025 - $PHR
Phreesia (PHR) Analyst Model Updated to Reflect Company’s Latest Financial Guidance for 2026-2027
Phreesia Inc. (NYSE:PHR) is one of the stocks that will double in 2026. On December 10, Baird lowered the firm’s price target on Phreesia to $25 from $31 with an Outperform rating on the shares. This announcement was made after the firm updated its model to reflect the company’s latest guidance for 2026-2027. Just a […] Dec 16, 2025 - $PHR
Phreesia (PHR) Is Down 19.9% After Profit Turnaround But Soft Revenue Outlook - What's Changed
In the past quarter, Phreesia, Inc. reported third-quarter fiscal 2026 revenue of US$120.33 million and net income of US$4.27 million, marking a move from a net loss a year earlier and lifting earnings per share from a loss of US$0.25 to a profit of US$0.07. Alongside this profit turnaround, Phreesia raised its fiscal 2026 revenue outlook and issued fiscal 2027 guidance, but the updated ranges trailed analyst expectations, creating a gap between improving results and more cautious forward... Dec 13, 2025 - $PHR
Is Phreesia a Hidden Opportunity After Recent Digital Patient Intake Partnerships?
Wondering if Phreesia at around $20 a share is a bargain in disguise or a value trap? You are not the only one trying to figure out what this healthcare tech name is really worth. The stock has been choppy lately, up about 0.5% over the last week, but still down roughly 8.6% over 30 days and 20.1% year to date. That suggests sentiment is still cautious despite a smaller recent bounce. Recent headlines have focused on Phreesia expanding its digital patient intake and engagement footprint with... Dec 9, 2025 - $PHR
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple